Redwood Pharma

1 following

ShowingAll content types

Regulatory press release7/28/2024, 12:30 PM

Redwood Pharma files for bankruptcy

Regulatory press release6/26/2024, 9:00 AM

Redwood Pharma provides a new update regarding divestment of company assets

Press release6/12/2024, 10:00 AM

Redwood Pharma provides an update on the process for divesting the company's assets

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release5/23/2024, 11:00 AM

Redwood Pharma provides an update on the company's future

Press release5/8/2024, 6:30 AM

Redwood Pharma's product RP501 attracted a lot of interest at ARVO in Seattle

Press release5/7/2024, 6:30 AM

Two international companies begin due diligence on Redwood Pharma's product RP501 ahead of potential commercial agreements

Press release5/6/2024, 1:00 PM

Redwood Pharma's board subscribes to units in the ongoing new issue

Press release2/28/2024, 7:30 AM

Redwood Pharma's innovative dry eye treatment to be presented at ARVO in Seattle

Press release12/20/2023, 8:10 AM

Redwood Pharma's CEO Martin Vidaeus in year-end interview

Press release12/19/2023, 7:00 AM

Redwood Pharma to participate in the JP Morgan Healthcare Conference

Regulatory press release11/30/2023, 7:30 AM

Redwood Pharma AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)

Press release11/22/2023, 7:30 AM

Redwood Pharma to participate in the NLS Days partner conference in Copenhagen

Press release10/19/2023, 9:15 AM

Redwood Pharma to participate in the BIO-Europe partnering conference in Munich

Regulatory press release5/31/2023, 9:10 PM

Redwood Pharma presents positive results from a clinical study with RP501 against dry eye

Press release3/17/2023, 12:00 PM

Redwood Pharma completes recruitment for clinical trial with RP501 for dry eye

Press release1/24/2023, 7:30 AM

Redwood Pharma takes important steps towards the commercial production of its dry eye product

Regulatory press release12/15/2022, 4:00 PM

Redwood Pharma enters partnership with Nextec medical in preparation for European market clearance of RP501

Press release10/19/2022, 1:18 PM

Interview with CEO Martin Vidaeus of Redwood Pharma at BioStock Investor Meeting, Stockholm

Press release10/14/2022, 6:30 AM

Redwood Pharma: Streamed video of CEO Martin Vidaeus presenting at Aktieportföljen Live in Stockholm, Sweden on Oct. 11, 2022

Press release10/3/2022, 1:42 PM

Redwood Pharma to present at AKTIEPORTFÖLJEN LIVE SVERIGE in Stockholm on 11[th] of Oct. 2022 at 14:45

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.